DK2493876T3 - Imidazolderivater som casein-kinaseinhibitorer - Google Patents

Imidazolderivater som casein-kinaseinhibitorer Download PDF

Info

Publication number
DK2493876T3
DK2493876T3 DK10774282.7T DK10774282T DK2493876T3 DK 2493876 T3 DK2493876 T3 DK 2493876T3 DK 10774282 T DK10774282 T DK 10774282T DK 2493876 T3 DK2493876 T3 DK 2493876T3
Authority
DK
Denmark
Prior art keywords
imidazol
fluorophenyl
pyrimidin
pharmaceutically acceptable
amine
Prior art date
Application number
DK10774282.7T
Other languages
English (en)
Inventor
Chakrapani Subramanyam
Travis T Wager
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK2493876T3 publication Critical patent/DK2493876T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (16)

1. Forbindelse med formel I:
eller farmaceutisk acceptable salte deraf, hvor: A er et nitrogenholdigt 4- til 7-leddet heterocycloalkyl, eller alternativt kan A vaere direkte kondenseret til den ring, til hvilken det er knyttet gennem R1; L er Ci-3alkyl; R1 er hydrogen, Ci-3alkyl eller C3-4cycloalkyl; hver R2 uafhaengigt er Ci-3alkyl, flúor, hydroxyl, Ci-3alkoxy eller cyano; R3 er hydrogen, Ci-3alkyl eller C3-4cycloalkyl; R4 er et 5- til 10-leddet heteroaryl med 1 til 3 heteroatomer, eventuelt substitueret med 1 til 3 R7 substituenter; R5 er hydrogen eller -N(R8)2; R6 er hydrogen, halogen eller Ci-3alkyl; hver R7 uafhaengigt er halogen, -(CH2)t-F, Ci-3alkyl, -CF3, -(CFI2)t-C3-4cycloalkyl, -(CH2)t-0-Ci-3alkyl, -(CFI2)t-cyano eller -(CFI2)t-hydroxy; ZerN eller -CR9; hver R8 uafhaengigt er hydrogen eller Ci-3alkyl; R9 er hydrogen, Ci-3alkyl eller halogen; m er 0, 1 eller 2; n er 0, 1 eller 2; t er 0, 1 eller 2.
2. Forbindelse ifolge krav 1 eller farmaceutisk acceptable salte deraf, hvor A er et nitrogenholdigt 4- til 7-leddet heterocycloalkyl, og
er forbundet med ring-N; L er C-ialkyl; hver R2 uafhaengigt er Ci-3alkyl eller flúor; hver R7 uafhaengigt er halogen, -(CH2)t-F, Ci-3alkyl, -CF3, -(CH2)t-C3-4cycloalkyl eller -(CH2)t-0-Ci.3alkyl.
3. Forbindelse ifolge krav 2 eller farmaceutisk acceptable salte deraf, hvor A er et nitrogenholdigt 5-leddet heterocycloalkyl, hvor heterocycloalkylet er nvrrolidin on
er forbundet med ring-N af pyrrolidin, og m er nul.
4. Forbindelse ifolge krav 2 eller farmaceutisk acceptable salte deraf, hvor A er et nitrogenholdigt 6-leddet heterocycloalkyl, hvor heterocycloalkylet er piperidin, og
er forbundet med ring-N af piperidin, og m er nul.
5. Forbindelse ifolge et hvilket som helst af de foregáende krav eller farmaceutisk acceptable salte deraf, hvor n er 1, og R7 er flúor.
6. Forbindelse ifolge et hvilket som helst af de foregáende krav eller farmaceutisk acceptable salte deraf, hvor Z er N, og R5 er -N(R8)2, hvor hver R8 er hydrogen.
7. Forbindelse ifolge et hvilket som helst af de foregáende krav eller farmaceutisk acceptable salte deraf, hvor R1 er hydrogen eller C-i-3alkyl.
8. Forbindelse ifolge et hvilket som helst af de foregáende krav eller farmaceutisk acceptable salte deraf, hvor R4 er et 5-leddet heteroaryl, hvor heteroarylet er en isoxazol, eventuelt substitueret med 1 eller 2 R7 substituenter, og t er nul.
9. Forbindelse ifclge et hvilket som helst af de foregáende krav eller farmaceutisk acceptable salte deraf, hvor R3 er hydrogen eller C1-3alkyl.
10. Forbindelse ifclge krav 1, der er udvalgt fra: 4-{4-(4-fluorphenyl)-1 -[1 -(pyrimidin-2-ylmethyl)piperidin-4-yl]-1 /-/-imidazol-5-yl}pyrimidin-2-amin; 4-{4-(4-fluorphenyl)-1 -[1 -(isoxazol-3-ylmethyl)piperid¡n-4-yl]-1 /-/-imidazol-5-yl}pyrimidin-2-amin; 4-{4-(4-fluorphenyl)-1 -[1 -(¡soxazol-3-ylmethyl)piperid¡n-4-yl]-1 /-/-imidazol-5-yl}-A/-methylpyrimidin-2-amin; 4-{4-(4-fluorphenyl)-1 -[1 -(isoxazol-3-ylmethyl)p¡peridin-4-yl]-1 /-/-imidazol-5-yljpyrimidin; 4-{4-(4-fluorphenyl)-1 -[1 -(isoxazol-3-ylmethyl)pyrrolidin-3-yl]-1 /-/-imidazol-5-yl}pyrimidin-2-amin; 2-{[4-(4-phenyl-5-pyrimid¡n-4-yl-1 H- imidazol-1 -yl)piperid¡n-1 -yl]methyl}pyrimidin; /V-methyl-4-{4-phenyl-1 -[1 -(pyrimidin-2-ylmethyl)piperidin-4-yl]-1 H-imidazol-5- yl}pyrimidin-2-amin; 4-{1 -[1 -(lsoxazol-3-ylmethyl)piperidin-4-yl]-4-phenyl-1 H-imidazol-5-yl}pyrimidin-2-amin; 4-{1 -[1 -(isoxazol-3-ylmethyl)piperidin-4-yl]-4-phenyl-1 /-/-imidazol-5-yl}-A/-methylpyrimidin-2-amin; 4-{4-(4-fluorphenyl)-1 -[1 -(1,3-thiazol-5-ylmethyl)piperidin-4-yl]-1 /-/-imidazol-5-yl}pyrimidin-2-amin; 4-[4-(4-fluorphenyl)-1 -{1 -[(2-methylpyridin-4-yl)methyl]piperidin-4-yl}-1 H-imidazol-5-yl]pyrimidin-2-amin; og 4-{4-(4-fluorphenyl)-1 -[1 -(pyridazin-4-ylmethyl)piperidin-4-yl]-1 H-imidazol-5-yl}pyrimidin-2-amin, 4-[4-(4-fluorphenyl)-1 -{1 -[(2-methylpyrimidin-5-yl)methyl]piperidin-4-yl}-1 H- imidazol-5-yl]pyrimidin-2-amin, eller farmaceutisk acceptable salte deraf.
11. Forbindelse ifolge et hvilket som helst af kravene 1-10 eller farmaceutisk acceptable salte deraf til anvendelse til inhibering af CK1 -delta- eller CK1-epsilon-aktivitet i en patient.
12. Forbindelse til anvendelse ifolge krav 11 eller farmaceutisk acceptable salte deraf, hvor inhiberingen af CK1-delta- eller CK1 -epsilon-aktivitet resulterer i en forlaengelse af perioden med cirkadisk rytme.
13. Forbindelse ifolge et hvilket som helst af kravene 1-10 eller farmaceutisk acceptable salte deraf til anvendelse til behandling af neurologisk eller psykiatrisk sygdom eller forstyrrelse.
14. Forbindelse til anvendelse ifolge krav 13 eller farmaceutisk acceptable salte deraf, hvor sygdommen eller forstyrrelsen er en stemningsforstyrrelse eller en sovnforstyrrelse.
15. Forbindelse til anvendelse ifolge krav 14 eller farmaceutisk acceptable salte deraf, hvor the stemningsforstyrrelsen er udvalgt fra gruppen bestáende af en depressiv forstyrrelse og en bipolaer forstyrrelse.
16. Farmaceutisk sammensaetning, der omfatter en forbindelse ifolge et hvilket som helst af kravene 1 til 10 eller et farmaceutisk acceptabelt salt deraf og en farmaceutisk acceptabel baerer.
DK10774282.7T 2009-10-28 2010-10-20 Imidazolderivater som casein-kinaseinhibitorer DK2493876T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25550609P 2009-10-28 2009-10-28
PCT/IB2010/054749 WO2011051858A1 (en) 2009-10-28 2010-10-20 Imidazole derivatives as casein kinase inhibitors

Publications (1)

Publication Number Publication Date
DK2493876T3 true DK2493876T3 (da) 2014-03-10

Family

ID=43301770

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10774282.7T DK2493876T3 (da) 2009-10-28 2010-10-20 Imidazolderivater som casein-kinaseinhibitorer

Country Status (22)

Country Link
US (1) US8518944B2 (da)
EP (1) EP2493876B1 (da)
JP (1) JP5784620B2 (da)
KR (1) KR101421852B1 (da)
CN (1) CN102686580B (da)
AR (1) AR078797A1 (da)
AU (1) AU2010311035B2 (da)
CA (1) CA2777632C (da)
DK (1) DK2493876T3 (da)
ES (1) ES2460065T3 (da)
HR (1) HRP20140252T1 (da)
IL (1) IL219190A0 (da)
IN (1) IN2012DN03182A (da)
MX (1) MX2012004997A (da)
PL (1) PL2493876T3 (da)
PT (1) PT2493876E (da)
RS (1) RS53246B (da)
SI (1) SI2493876T1 (da)
TW (1) TW201125864A (da)
UY (1) UY32977A (da)
WO (1) WO2011051858A1 (da)
ZA (1) ZA201202776B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
LT3181133T (lt) * 2010-12-20 2019-09-25 Pfizer Inc. Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
JP6267231B2 (ja) 2012-12-21 2018-01-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
EP3006438A4 (en) 2013-05-30 2017-01-18 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
WO2015119579A1 (en) 2014-02-07 2015-08-13 Agency For Science, Technology And Research 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
CN107847480B (zh) 2015-03-23 2021-06-25 墨尔本大学 呼吸性疾病的治疗
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
PT3619204T (pt) * 2017-05-03 2025-10-29 Tianli Biotech Pty Ltd Compostos para o tratamento de doenças respiratórias
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
MX2021002652A (es) * 2018-09-09 2021-09-23 Qanatpharma Ag Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
JP7575099B2 (ja) * 2018-11-07 2024-10-29 ティアンリ バイオテック プロプライエタリ リミテッド 呼吸器疾患の処理のための新規な化合物
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
CN115335057A (zh) * 2020-03-27 2022-11-11 北京原基华毅生物科技有限公司 抑制酪蛋白激酶的方法
EP4126878A4 (en) * 2020-03-27 2024-07-10 Gritscience Biopharmaceuticals Co., Ltd. COMPOUNDS AS CASEIN KINASE INHIBITORS
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012154A1 (en) * 1990-12-31 1992-07-23 Fujisawa Pharmaceutical Co., Ltd. Imidazotriazine derivatives
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
IL159416A0 (en) * 2001-06-18 2004-06-01 Univ Rockefeller Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
DE602004020685D1 (de) * 2003-12-11 2009-05-28 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
BRPI0514397A (pt) * 2004-08-19 2008-06-10 Aventis Pharma Inc derivados de 3-ariltioindol-2-carboxamida e análogos destes como inibidores de caseìna cinase iépsilon
CA2626789A1 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
LT3181133T (lt) * 2010-12-20 2019-09-25 Pfizer Inc. Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai

Also Published As

Publication number Publication date
AR078797A1 (es) 2011-12-07
US8518944B2 (en) 2013-08-27
AU2010311035B2 (en) 2013-05-16
JP5784620B2 (ja) 2015-09-24
US20110098272A1 (en) 2011-04-28
PT2493876E (pt) 2014-03-20
PL2493876T3 (pl) 2014-06-30
HRP20140252T1 (hr) 2014-04-25
CN102686580B (zh) 2014-09-10
KR20120088759A (ko) 2012-08-08
EP2493876B1 (en) 2014-02-12
CA2777632C (en) 2014-02-25
WO2011051858A1 (en) 2011-05-05
KR101421852B1 (ko) 2014-07-22
EP2493876A1 (en) 2012-09-05
UY32977A (es) 2011-05-31
TW201125864A (en) 2011-08-01
MX2012004997A (es) 2012-06-12
ES2460065T3 (es) 2014-05-13
ZA201202776B (en) 2013-06-26
RS53246B (sr) 2014-08-29
CA2777632A1 (en) 2011-05-05
IN2012DN03182A (da) 2015-09-25
JP2013509392A (ja) 2013-03-14
IL219190A0 (en) 2012-06-28
HK1171220A1 (en) 2013-03-22
AU2010311035A1 (en) 2012-05-03
CN102686580A (zh) 2012-09-19
SI2493876T1 (sl) 2014-04-30

Similar Documents

Publication Publication Date Title
DK2493876T3 (da) Imidazolderivater som casein-kinaseinhibitorer
EP3181133B1 (en) Novel fused pyridine compounds as casein kinase inhibitors
US20110224231A1 (en) Novel Lactams as Beta Secretase Inhibitors
US20120202787A1 (en) Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators
EP2300484A1 (en) Novel class of spiro piperidines for the treatment of neurodegenerative diseases
US20130150376A1 (en) Novel Sultam Compounds
HK1171220B (en) Imidazole derivatives as casein kinase inhibitors